Payment overview · 2025
General Payments
$139.03
2 reported records · 2 companies
Healthcare provider profile · identity verified
Steven E Knaus, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEENAH, WI · NPI 1457332215
Verified facts
What the public records show
CMS Open Payments records show Steven E Knaus, MD received $139.03 in general payments during 2025 across 2 reported records.
AstraZeneca Pharmaceuticals LP accounted for 90.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 419 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $125.50 | 90.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.53 | 9.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $125.50 | 1 |
| Education | $13.53 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.50 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY Normalized: abilify |
Drug | E.R. Squibb & Sons, L.L.C. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
419 | 91 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 672 | 187 |
| Losartan Potassium | Losartan Potassium | 643 | 171 |
| Simvastatin | Simvastatin | 574 | 143 |
| Atorvastatin Calcium | Atorvastatin Calcium | 546 | 150 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 482 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 480 | 120 |
| Furosemide | Furosemide | 423 | 124 |
| Eliquis | Apixaban | 419 | 91 |
| Metoprolol Tartrate | Metoprolol Tartrate | 370 | 102 |
| Omeprazole | Omeprazole | 352 | 104 |
| Metformin Hcl | Metformin Hcl | 334 | 85 |
| Lisinopril | Lisinopril | 324 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 304 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 51 |
| Gabapentin | Gabapentin | 196 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 196 | 57 |
| Pioglitazone Hcl | Pioglitazone Hcl | 194 | 47 |
| Carvedilol | Carvedilol | 183 | 51 |
| Alendronate Sodium | Alendronate Sodium | 178 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 175 | 51 |
| Sertraline Hcl | Sertraline Hcl | 170 | 41 |
| Meloxicam | Meloxicam | 168 | 47 |
| Allopurinol | Allopurinol | 150 | 38 |
| Finasteride | Finasteride | 148 | 39 |
| Warfarin Sodium | Warfarin Sodium | 148 | 42 |
| Celecoxib | Celecoxib | 146 | 45 |
| Potassium Chloride | Potassium Chloride | 140 | 32 |
| Prednisone | Prednisone | 125 | 83 |
| Alprazolam | Alprazolam | 121 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 113 | 76 |
| Tramadol Hcl | Tramadol Hcl | 113 | 28 |
| Donepezil Hcl | Donepezil Hcl | 112 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 42 |
| Metformin Hcl Er | Metformin Hcl | 93 | 30 |
| Clonazepam | Clonazepam | 86 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 24 |
| Atenolol | Atenolol | 81 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 80 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 78 | 21 |
| Montelukast Sodium | Montelukast Sodium | 77 | 19 |
| Trazodone Hcl | Trazodone Hcl | 77 | 24 |
| Famotidine | Famotidine | 76 | 19 |
| Bupropion Xl | Bupropion Hcl | 75 | 17 |
| Fenofibrate | Fenofibrate | 70 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 20 |
| Xarelto | Rivaroxaban | 67 | 14 |
| Ozempic | Semaglutide | 66 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 16 |
| Glipizide | Glipizide | 56 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 15 |
| Valsartan | Valsartan | 55 | 16 |
| Synthroid | Levothyroxine Sodium | 54 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 14 |
| Spironolactone | Spironolactone | 53 | 16 |
| Ezetimibe | Ezetimibe | 51 | 17 |
| Lorazepam | Lorazepam | 51 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 11 |
| Amoxicillin | Amoxicillin | 44 | 30 |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Jardiance | Empagliflozin | 43 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 42 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 42 | 11 |
| Cephalexin | Cephalexin | 40 | 26 |
| Diazepam | Diazepam | 40 | suppressed |
| Estradiol | Estradiol | 38 | 16 |
| Lovastatin | Lovastatin | 38 | suppressed |
| Nystatin | Nystatin | 38 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 29 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Loperamide | Loperamide Hcl | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 27 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 24 |
| Baclofen | Baclofen | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 23 |
| Nitroglycerin | Nitroglycerin | 25 | 18 |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 18 |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 11 |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $139.03 · 2 records | AstraZeneca Pharmaceuticals LP | ABILIFY, BREZTRI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error